Download Free Medical Thrombophilia-Hypercoagulable States PowerPoint Presentation

Thrombophilia-Hypercoagulable States PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Thrombophilia - Hypercoagulable States” by Gabriel Shapiro, MD, FACP.

This medical PowerPoint presentation is about thrombophilia, a medical condition characterized by an increased tendency to develop blood clots (hypercoagulable state) due to abnormalities in the blood clotting system. These abnormalities can be genetic or acquired and can increase the risk of developing deep vein thrombosis (DVT), pulmonary embolism (PE), and other thrombotic disorders.

There are many different causes of thrombophilia, including genetic mutations, hormonal imbalances, medications, and medical conditions such as cancer, pregnancy, and autoimmune diseases. Some common genetic mutations associated with thrombophilia include Factor V Leiden, prothrombin G20210A, and protein C and S deficiency.

People with thrombophilia may not experience any symptoms until a clot develops, which can be life-threatening if it occurs in a critical organ such as the brain or lungs. Symptoms of DVT include pain, swelling, warmth, and redness in the affected area, while symptoms of PE can include shortness of breath, chest pain, coughing, and rapid heart rate.

Treatment for thrombophilia typically involves blood thinning medications such as anticoagulants to reduce the risk of blood clots. Lifestyle modifications such as regular exercise, weight loss, and avoiding smoking can also help to reduce the risk of developing blood clots. People with thrombophilia may need to take anticoagulants for a long time or even for life, depending on the underlying cause and risk factors.

Tags : Thrombophilia, Hypercoagulable States, blood clots, deep vein thrombosis, pulmonary embolism, thrombotic disorders, Hematology, Hematology PowerPoint presentation

Published on : May 29, 2023 | Views : 997 | Downloads : 2

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Thrombophilia—Hypercoagulable States Gabriel Shapiro, MD, FACP
Slide 2-

Thrombosis Hereditary thrombophilia Acquired thrombophilia Surgery trauma Immobility Inflammation Malignancy Estrogens Risk Factors for Thrombosis Atherosclerosis
Slide 3-

Risk Factors forVenous Thrombosis Acquired Inherited Mixed/unknown
Slide 4-

Risk Factors—Acquired Advancing age Prior Thrombosis Immobilization Major surgery Malignancy Estrogens Antiphospholipid antibody syndrome Myeloproliferative Disorders Heparin-induced thrombocytopenia (HIT) Prolonged air travel
Slide 5-

Risk Factors—Inherited Antithrombin deficiency Protein C deficiency Protein S deficiency Factor V Leiden mutation (Factor V-Arg506Gln) Prothrombin gene mutation (G A transition at position 20210) Dysfibrinogenemias (rare)
Slide 6-

Risk Factors—Mixed/Unknown Hyperhomocysteinemia High levels of factor VIII Acquired Protein C resistance in the absence of Factor V Leiden High levels of Factor IX, XI
Slide 7-

Genetic Thrombophilic Defects Influence the Risk of a First Episode of Thrombosis
Slide 8-

Prevalence of DefectsIn Patients with Venous Thrombosis Thrombophilic Defect Rel. Risk Antithrombin deficiency 8 – 10 Protein C deficiency 7 – 10 Protein S deficiency 8 – 10 Factor V Leiden/APC resisance 3 – 7 Prothrombin 20210 A muation 3 Elevated Factor VIII 2 – 11 Lupus Anticoagulant 11 Anticardiolipin antibodies 1.6-3.2 Mild hyperhomocysteinemia 2.5
Slide 9-

Risk vs. Incidence ofFirst Episode of Venous Thrombosis Risk Incidence/year (%) Normal 1 .008 Oral Cont. Pills 4x .03 Factor V Leiden 7x .06 (heterozygote) OCP + Factor V L. 35x .3 Factor V Leiden 80x .5-1 homozygotes
Slide 10-

Risk of Recurrent Venous Thromboembolism (VTE) in Thrombophilia Compared to VTE Without a Thrombophilic Defect Thrombophilic Defect Rel. Risk Antithrombin, protein C, 2.5 or protein S deficiency Factor V Leiden mutation 1.4 Prothrombin 20210A mutation 1.4 Elevated Factor VIII:c 6 – 11 Mild hyperhomocysteinemia 2.6 – 3.1 Antiphospholipid antibodies 2 – 9
Slide 11-

Other Predictors for Recurrent VTE Idiopathic VTE Residual DVT Elevated D-dimer levels Age Sex
Slide 12-

FXI FIX FXII FV FVII Prothrombin Thrombin Fibrinogen Fibrin Clot FVIII FX
Slide 13-

J Thromb. Haem.1.525, 2003
Slide 14-

Antithrombin,Antithrombin Deficiency Also known as Antithrombin III Inhibits coagulation by irreversibly binding the thrombogenic proteins thrombin (IIa), IXa, Xa, XIa and XIIa Antithrombin’s binding reaction is amplified 1000-fold by heparin, which binds to antithrombin to cause a conformational change which more avidly binds thrombin and the other serine proteases
Slide 15-

ppt slide no 15 content not found
Slide 16-

ppt slide no 16 content not found
Slide 17-

ppt slide no 17 content not found
Slide 18-

ppt slide no 18 content not found
Slide 19-

ppt slide no 19 content not found
Slide 20-

Protein C andProtein C Deficiency Protein C is a vitamin K dependent glycoprotein produced in the liver In the activation of protein C, thrombin binds to thrombomodulin, a structural protein on the endothelial cell surface This complex then converts protein C to activated protein C (APC), which degrades factors Va and VIIIa, limiting thrombin production For protein C to bind, cleave and degrade factors Va and VIIIa, protein S must be available Protein C deficiency, whether inherited or acquired, may cause thrombosis when levels drop to 50% or below Protein C deficiency also occurs with surgery, trauma, pregnancy, OCP, liver or renal failure, DIC,or warfarin
Slide 21-

ppt slide no 21 content not found
Slide 22-

Protein S, C4b Binding Protein,and Protein S Deficiency Protein S is an essential cofactor in the protein C pathway Protein S exists in a free and bound state 60-70% of protein S circulates bound to C4b binding proten The remaining protein S, called free PS, is the functionally active form of protein S Inherited PS deficiency is an autosomal dominant disorder, causing thrombosis when levels drop to 50% or lower
Slide 23-

Causes of Acquired Protein S Deficiency May be due to elevated C4bBP, decreased PS synthesis, or increased PS consumption C4bBP is an acute phase reactant and may be elevated in inflammation, pregnancy, SLE, causing a drop in free PS Functional PS activity may be decreased in vitamin K deficiency, warfarin, liver disease Increased PS consumption occurs in acute thrombosis, DIC, MPD, sickle cell disease
Slide 24-

Activated Protein C (APC) ResistanceDue to Factor V Leiden Activated protein C (APC) is the functional form of the naturally occurring, vitamin K dependent anticoagulant, protein C APC is an anticoagulant which inactivates factors Va and VIIIa in the presence of its cofactor, protein S Alterations of the factor V molecule at APC binding sites (such as amino acid 506 in Factor V Leiden) impair, or resist APC’s ability to degrade or inactivate factor Va
Slide 25-

J Thromb Haem 1. 525, 2003
Slide 26-

Prothrombin G20210A Mutation A G-to-A substitution in nucleotide position 20210 is responsible for a factor II polymorphism The presence of one allele (heterozygosity) is associated with a 3-6 fold increased for all ages and both genders The mutation causes a 30% increase in prothrombin levels.
Slide 27-

Antiphospholipid Syndrome
Slide 28-

Antiphospholipid Syndrome—Diagnosis Clinical Criteria -Arterial or venous thrombosis -Pregnancy morbidity Laboratory Criteria -IgG or IgM anticardiolipin antibody-medium or high titer -Lupus Anticoagulant
Slide 29-

Antiphospholipid Syndrome—Clinical Thrombosis—arterial or venous Pregnancy loss Thrombocytopenia CNS syndromes—stroke, chorea Cardiac valve disease Livedo Reticularis
Slide 30-

Antiphospholipid Syndrome—The Lupus Anticoagulant (LAC) DRVVT- venom activates F. X directly; prolonged by LAC’s APTT- Usually prolonged, does not correct in 1:1 mix Prothrombin Time- seldom very prolonged
Slide 31-

Antiphospholipid Syndrome—Anticardiolipin Antibodies ACAs are antibodies directed at a protein-phosholipid complex Detected in an ELISA assay using plates coated with cardiolipin and B2-glycoprotein
Slide 32-

Antiphospholipid Syndrome—Treatment Patients with thrombosis- anticoagulation, INR 3 Anticoagulation is long-term—risk of thrombosis is 50% at 2 years after discontinuation Women with recurrent fetal loss and APS require LMW heparin and low-dose heparin during their pregnancies
Slide 33-

Heparin-Induced Thrombocytopenia(HIT) HIT is mediated by an antibody that reacts with a heparin-platelet factor 4 complex to form antigen-antibody complexes These complexes bind to the platelet via its Fc receptors Cross-linking the receptors leads to platelet aggregation and release of platelet factor 4 (PF4) The released PF4 reacts with heparin to form heparin-PF4 complexes, which serve as additional sites for HIT antibody binding
Slide 34-

J Thromb Haem 1,1471, 2003
Slide 35-

Diagnosis of HIT Diagnosis made on clinical grounds HIT usually results in thrombosis rather than bleeding Diagnosis should be confirmed by either immunoassay (ELISA) or functional tests (14C serotonin release assay) Treatment involves cessation of heparin, treatment with an alternative drug, e.g. argatroban, and switching to warfarin
Slide 36-

Thrombophilia:How Do You DecideWho to Test?
Slide 37-

Site of Thrombosis vs. Coag. Defect Abnormality Arterial Venous Factor V Leiden - + Prothrombin G20210A - + Antithrombin deficiency - + Protein C deficiency - + Protein S deficiency - + Hyperhomocysteinemia + + Lupus Anticoagulant + +
Slide 38-

Stratification of Potentially Thombophilic Patients Clinical History “Weekly” “Strongly” Age of onset <50 - + Recurrent thrombosis - + Positive family history - +
Slide 39-

Testing for Hereditary Defectsin Patients With ThrombosisWith No Family History Pro Improve understanding of pathogenesis of thrombosis Identify and counsel affected family members Obviate expensive diagnostic testing (e.g. CT scans) looking for a malignancy Con Infrequent identification of patients with defects whose management would change Potential for overaggressive management Insurance implications Cost of testing
Slide 40-

Clinical Implications In Treatment of Thrombophilia Routine screening of patients with VTE for an underlying thrombophilic defect “is not justified” However, the risk of subsequent thrombosis over 5 years in men with idiopathic VTE is 30% Any additional defect adds to risk and to possible need for prolongation of anticoagulation Furthermore, women with a history of VTE who wish to become pregnant will be treated differently if a defect were found
Slide 41-

Screening EvaluationFor “Strongly Thrombophilic” Patients Test for Factor V Leiden Genetic test for prothrombin gene mutation 20210A Functional assay of antithrombin Functional assay of protein C Functional assay of protein S Clotting test for lupus anticoagulant/ELISA for cardiolipin antibodies Measurement of fasting total plasma homocysteine
Slide 42-

Screening Laboratory EvaluationFor “Weekly Thrombophilic” Patients Test for Factor V Leiden Genetic test for prothrombin gene mutation G20210A Measurement of fasting total plasma homocysteine Clotting assay for lupus anticoagulant/ELISA for cardiolipin antibodies
Slide 43-

Management of PatientsWith Thrombophilia Risk Classification Management High Risk 2 or more spontaneous events Indefinite Anticoagulation 1 spontaneous life-threatening event (near-fatal pulmonary embolus, cerebral, mesenteric, portal vein thrombosis) 1 spontaneous event in association with antiphospholipid antibody syndrome, antithrombin deficiency, or more than 1 genetic defect Moderate Risk 1 event with a known provocative Vigorous prophylaxis in stimulus high-risk settings Asymptomatic
Slide 44-

ppt slide no 44 content not found